Literature DB >> 30896263

Immunostaining characteristics of irisin in benign and malignant renal cancers.

T Kuloğlu1, G Artaş2, M Yardim3, I Sahin3,4, Y Aydin5, N Beyoğlu6, I H Özercan2, M H Yalcin7, K Ugur8, S Aydin3.   

Abstract

We investigated the expression of irisin in renal cancers using immunocytochemistry. Irisin has been reported to exhibit anticancer properties. The study groups consisted of 22 cases each of control renal tissue, oncocytoma, chromophobe renal cell carcinoma (RCC), clear cell RCC (Fuhrman nuclear grades 1, 2, 3 and 4) and papillary RCC. We evaluated 10 slides for each of 176 cases. Slides were immunostained for irisin and histoscores were calculated for the prevalence and strength of immunostaining. Fuhrman nuclear grade 1, 2, 3 clear cell RCC and papillary RCC exhibited no irisin immunoreactivity. Irisin immunoreactivity was observed in some Fuhrman nuclear grade 4 RCCs. We found a significant decrease in irisin staining in chromophobe RCC compared to the control. Immunoreactivity in the oncocytoma tissue was comparable to the control group. Irisin immunoreactivity in chromophobe RCC decreased and no immunoreactivity was observed in Fuhrman nuclear grade 1, 2, 3 clear cell RCC and papillary RCC. Immunistochemical screening of irisin in renal oncocytomas and renal cancers may be useful for differential diagnosis.

Entities:  

Keywords:  Cancer; Fuhrman nuclear grade; chromophobe RCC; clear cell RCC; irisin; oncocytoma; renal tissue

Mesh:

Substances:

Year:  2019        PMID: 30896263     DOI: 10.1080/10520295.2019.1586998

Source DB:  PubMed          Journal:  Biotech Histochem        ISSN: 1052-0295            Impact factor:   1.718


  5 in total

1.  Can the Irisin be a Biomarker for Prostate Cancer? A Case Control Study.

Authors:  Rahmi Aslan; Hamit Hakan Alp; Recep Eryılmaz; Zubeyir Huyut; Mehmet Sevim; Şeyhmuz Araz; Kasim Ertas; Kerem Taken
Journal:  Asian Pac J Cancer Prev       Date:  2020-02-01

Review 2.  Implication of Irisin in Different Types of Cancer: A Systematic Review and Meta-Analysis.

Authors:  Maria Vliora; Eleni Nintou; Eleni Karligiotou; Leonidas G Ioannou; Elisabetta Grillo; Stefania Mitola; Andreas D Flouris
Journal:  Int J Mol Sci       Date:  2022-09-01       Impact factor: 6.208

Review 3.  Current Evidence of the Role of the Myokine Irisin in Cancer.

Authors:  Evangelia Tsiani; Nicole Tsakiridis; Rozalia Kouvelioti; Alina Jaglanian; Panagiota Klentrou
Journal:  Cancers (Basel)       Date:  2021-05-27       Impact factor: 6.639

Review 4.  Review of Research on the Role of Irisin in Tumors.

Authors:  Zengyin Chen; Guangjun Shi; Deguo Zhang; Xueying Tan; Nan Tang; Fei Huang
Journal:  Onco Targets Ther       Date:  2020-05-19       Impact factor: 4.147

5.  Irisin Association with Ki-67, MCM3 and MT-I/II in Squamous Cell Carcinomas of the Larynx.

Authors:  Agnieszka Pinkowska; Katarzyna Nowinska; Urszula Ciesielska; Marzenna Podhorska-Okolow
Journal:  Biomolecules       Date:  2021-12-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.